Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)

Completed · Phase 1/Phase 2

Conditions studied: Lung Cancer

In brief

The purpose of this study is to determine the safety, tolerability and maximum tolerated dose of IPI-504 in patients with non-small cell lung cancer (NSCLC). The study will examine how IPI-504 is absorbed, distributed, metabolized and eliminated by the body. The study will also evaluate the anti-tumor activity of IPI-504.

Key facts

Study ID

NCT00431015

Run by

Infinity Pharmaceuticals, Inc.

People needed

88

Starts

2007-01-01

Expected to finish

2011-12-01

Last updated by the study team

2012-12-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Pathologically confirmed diagnosis of a Stage IIIb (with malignant pleural or pericardial effusion) or Stage IV NSCLC
• Measurable disease by RECIST criteria.

You may not qualify if…

• Treatment for NSCLC with any approved or investigational product within 2 weeks of the start of IPI-504 treatment for any small molecule therapy; within 4 weeks of the start of IPI-504 treatment for any biologic or any conventional chemotherapy.
• Inadequate hematologic or renal or hepatic function
• Previous treatment with 17-AAG, DMAG or other known Hsp90 inhibitor.

Where it is running

• Cedars-Sinai Medical Center — Los Angeles, California, United States
• Yale Comprehensive Cancer Center — New Haven, Connecticut, United States
• Mount Sinai Comprehensive Cancer Center — Miami, Florida, United States
• H. Lee Moffitt Cancer Center — Tampa, Florida, United States
• Medical College of Georgia — Augusta, Georgia, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States
• Hackensack University Medical Center — Hackensack, New Jersey, United States
• Mary Crowley Cancer Research Centers - Medical City — Dallas, Texas, United States
• Mary Crowley Cancer Research Centers - Baylor — Dallas, Texas, United States
• Seattle Cancer Care Alliance — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.